[Current Data] Rule running report - 2024-03-30 07:47:43.859151

Nr2MedPage Today) -- SAN DIEGO -- Treatment with raludotatug deruxtecan (R-DXd) led to an "exciting" response rate among patients with heavily pretreated, platinum-resistant advanced ovarian cancer, according to an early-phase… succesfully run! 0 Anläufe!